Milestone Healthcare

Lenavatinib Capsules 10 mg for treatment of Cancer
Established in the year 2011 at Vadodara (Gujarat, India), “Milestone Healthcare” are a Sole Proprietorship firm engaged in wholesaling, trading and exporting an excellent quality range of Pharmaceutical Tablet and Pharmaceutical Injection. These pharma products are sourced from reliable market vendors and can be availed by our clients at reasonable prices. Under the guidance of “Mr. Gitesh Jaiswal”,

Temozolomide Capsules IP 20 mg
Established in the year 2011 at Vadodara (Gujarat, India), “Milestone Healthcare” are a Sole Proprietorship firm engaged in wholesaling, trading and exporting an excellent quality range of Pharmaceutical Tablet and Pharmaceutical Injection. These pharma products are sourced from reliable market vendors and can be availed by our clients at reasonable prices. Under the guidance of “Mr. Gitesh Jaiswal”,

Palbociclib is a kinase inhibitor indicated in • Combination with Letrozole for the treatment of postmenopausal women with estrogen receptor (ER)- Positive, human epidermal growth factor receptor 2 (HER2)-Negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. • Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- Negative advanced or metastatic breast cancer in combination with: fulvestrant in women with disease progression following endocrine therapy.

Palbociclib is a kinase inhibitor indicated in • Combination with Letrozole for the treatment of postmenopausal women with estrogen receptor (ER)- Positive, human epidermal growth factor receptor 2 (HER2)-Negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. • Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- Negative advanced or metastatic breast cancer in combination with: fulvestrant in women with disease progression following endocrine therapy.

Palbociclib is a kinase inhibitor indicated in • Combination with Letrozole for the treatment of postmenopausal women with estrogen receptor (ER)- Positive, human epidermal growth factor receptor 2 (HER2)-Negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. • Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- Negative advanced or metastatic breast cancer in combination with: fulvestrant in women with disease progression following endocrine therapy.

Temozolomide Capsules IP 100 mg
Established in the year 2011 at Vadodara (Gujarat, India), “Milestone Healthcare” are a Sole Proprietorship firm engaged in wholesaling, trading and exporting an excellent quality range of Pharmaceutical Tablet and Pharmaceutical Injection. These pharma products are sourced from reliable market vendors and can be availed by our clients at reasonable prices. Under the guidance of “Mr. Gitesh Jaiswal”,

Colours: Red Oxide of Iron and Titanium Dioxide DOSAGE FORM Oral tablet Capecitabine is a non-cytotoxic fluoropyrimidine carbamate, which functions as an orally administered precursor of the cytotoxic moiety of (5-FU). The enzyme involved in the final conversion to 5-FU, thymidine Th ' 5-fluorouracil (5-FU).

Chewable tablet- Each chewable tablet contains Sucroferric Oxyhydroxide (2500 mg) equivalent to Iron 500 mg . Brown, circular, bi-planar tablets with white speckle,plain on both sides and contains a Chocolate flavour. Indications And Usage: Sucroferric oxyhydroxide is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

Xbira medicines are used together with prednisone to treat prostate cancer that has spread to other parts of the body. The provided tablet is processed using top grade chemical compounds and latest techniques under experts' guidance. This tablet is mainly used to treat prostate cancer in human.

Lapatinib in combination with capecitabine, is indicated for the treatment or Tents with advanced or metastatic breast cancer whose tumour overexpress HER2-Uneu (ErbB2) and who have received prior therapy including trastuzumab. In combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib in combination with trastuzumab, indicated for the treatment of patients with hormone receptor- negative metastatic breast cancer whose tumours overexpress IIER21rieu kErbB2) and who have progressed on prior trastuzumab therapy in combination with chemotherapy in the metastatic setting.

• Adjuvant treatment of postmenopausal women hormone receptor positive invasive early breast cancer

Treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous

CLINICAL INFORMATION Indications: Multiple Myeloma Lenalidomide in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. Myelodysplastic Syndromes: Lenalidomide is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Hydroxyurea is used to treat a certain type of chronic myelogenous lukemia